RNA
Companies
NASDAQ
Avidity Biosciences Inc.
Health Care
$29.36
+$0.23 (+0.79%)
Price Chart
Overview
About RNA
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Market Cap
$2.5B
Volume
41.1M
Avg. Volume
44.2M
P/E Ratio
-10.442245
Dividend Yield
0.00%
Employees
226.0
Company Information
Latest News for RNA
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
September 24, 2024
If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong
November 18, 2022
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
May 8, 2025
Risk & Correlation Analysis
Market Correlation
0.77
Moderate Correlation
Volatility
High (0.66)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RNA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.5B
Volume41.1M
P/E Ratio-10.44
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025